What to ask a clinic about federal approval

What to ask about the exact treatment

Ask whether that exact treatment has approval for your sore joint. Don't settle for an answer about the clinic itself.

Get the treatment name and the answer in writing. Staff should explain the words without changing the subject.

Ask what facts support the care being offered. The facts need to cover that same treatment and joint.

What to know when you hear registered

Registration is the filing of a name and business details. It isn't a review showing that joint care works.

Think of it as a name in a public book. The listing doesn't grade the treatment.

When to stop and ask again

Slow down when one treatment is said to fix many unrelated problems. Your sore joint needs an exam, not a wide promise.

Don't pay while the full price remains unclear. Get the cost of later visits and repeat care on paper.

Leave if simple questions bring pressure or anger. Another doctor can read the offer with you.

What to do if it doesn't settle

Your regular doctor can review the name and written offer. You don't need to decide while someone rushes you.

For soreness that stays, QC Kinetix can discuss regenerative treatments, procedures made from material in your body. The clinic calls those who examine your joint and perform care medical providers.

Ask how federal rules apply before agreeing to anything. You'll want the answer in writing.

Sources

1. FDA states in its consumer alert that the only FDA-approved stem cell products in the United States are blood-forming stem cells derived from umbilical cord blood, approved for disorders of the blood-forming system, and that NONE of these products - stem cells, stromal vascular fraction, umbilical cord blood, Wharton's jelly or amniotic fluid - has been approved for the treatment of any orthopedic condition, including osteoarthritis, tendonitis, disc disease, tennis elbow, back pain, hip pain, knee pain, neck pain or shoulder pain.

   US Food and Drug Administration, Center for Biologics Evaluation and Research — Consumer Alert on Regenerative Medicine Products Including Stem Cells and Exosomes. , 2020.

2. 21 CFR 1271.10(a) sets the four criteria a human cell or tissue product must meet to be regulated SOLELY under section 361 of the Public Health Service Act: it must be minimally manipulated; intended for homologous use only, as reflected by labeling and advertising; not combined with another article beyond water, crystalloids or a preserving agent; and either have no systemic effect and not depend on the metabolic activity of living cells, or else be for autologous use, use in a close blood relative, or reproductive use.

   US Code of Federal Regulations, Title 21 — 21 CFR 1271.10 - Are my HCT/P's regulated solely under section 361 of the PHS Act. , 2004.

3. On 27 September 2024 the Ninth Circuit held in United States v. California Stem Cell Treatment Center that stromal vascular fraction produced by enzymatically digesting a patient's own fat IS a drug under the Federal Food, Drug, and Cosmetic Act, and that the same surgical procedure exception does not apply because the removed fat and the implanted SVF are not the same thing. The district court's ruling for the clinics was reversed.

   United States Court of Appeals for the Ninth Circuit — United States v. California Stem Cell Treatment Center, Inc., No. 22-56014 (9th Cir. Sept. 27, 2024). , 2024.

4. MACI is FDA-licensed (STN BL 125603, Vericel Corporation) and is indicated for the repair of symptomatic, single or multiple FULL-THICKNESS cartilage defects of the knee with or without bone involvement in adults - a focal defect repair performed surgically, not a treatment for osteoarthritis and not an injection.

   US Food and Drug Administration — MACI (autologous cultured chondrocytes on porcine collagen membrane). , 2016.

5. FDA's list of licensed cellular and gene therapy products is the checkable public record of what has actually been approved; the orthopedic entry on it is MACI (autologous cultured chondrocytes on porcine collagen membrane), and the cord blood entries (HEMACORD, ALLOCORD, DUCORD and others) are hematopoietic products for blood disorders, not joint treatments.

   US Food and Drug Administration, Office of Therapeutic Products — Approved Cellular and Gene Therapy Products. , 2026.

6. The 2018 AAOS/NIH consensus work group recommended that minimally manipulated mixed cell preparations be called CELL THERAPY rather than stem cell therapy, and that their untested and uncharacterised nature be clearly communicated to patients and the public, because stem cells have properties these preparations do not meet.

   Chu CR, et al. — Optimizing Clinical Use of Biologics in Orthopaedic Surgery: Consensus Recommendations From the 2018 AAOS/NIH U-13 Conference. J Am Acad Orthop Surg, 2019. DOI: 10.5435/JAAOS-D-18-00305.